References:
1. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between
inflammation and coagulation. The Lancet Respiratory . April
2020:1-2. doi:10.1016/S2213-2600(20)30216-2.
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study. The Lancet .
2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.
3. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R. MMWR
- Hospitalization Rates and Characteristics of Patients Hospitalized
with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14
States, March 1–30, 2020. CDC MMWR . 2020;69(15):458-464.
4. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J. A comparative study on
the clinical features of COVID-19 pneumonia to other pneumonias.Clin Infect Dis . March 2020:1-21.
doi:10.1093/cid/ciaa247/5803302.
5. Nur E, Gaartman AE, Tuijn CFJ, Tang MW, Biemond BJ. Vaso‐occlusive
crisis and acute chest syndrome in sickle cell disease due to 2019 novel
coronavirus disease (COVID‐19). Am J Hematol . April 2020.
doi:10.1002/ajh.25821.
6. Zaidi GZ, Rosentsveyg JA, Fomani KF, Louie JP, Koenig SJ. Reversal of
Severe Multiorgan Failure Associated with Sickle Cell Crisis Using
Plasma Exchange: A Case Series. J Intensive Care Med .
2019;35(2):140-148. doi:10.1177/0885066619874041.
7. Fortenberry JD, Nguyen T, Grunwell JR, et al. Therapeutic Plasma
Exchange in Children with Thrombocytopenia-Associated Multiple Organ
Failure. Critical Care Medicine . 2019;47(3):e173-e181.
doi:10.1097/CCM.0000000000003559.
8. McCollom JW, Dublis SA, Hoogeboom J, Doyle A, Templin J. Catastrophic
Multi-Organ Failure with Bone Marrow Necrosis in a Sickle Cell Beta Plus
Thalassemia Patient. Blood . 2014;124(21):4942-4942.
doi:10.1182/blood.V124.21.4942.4942.
9. Kim HC. Red cell exchange: special focus on sickle cell disease.Hematology . 2014;2014(1):450-456.
doi:10.1182/asheducation-2014.1.450.
10. Banerjee S, Owen C, Chopra S. Sickle cell hepatopathy.Hepatology . 2001;33(5):1021-1028. doi:10.1053/jhep.2001.24114.
11. Allali S, de Montalembert M, Brousse V, et al. Hepatobiliary
Complications in Children with Sickle Cell Disease: A Retrospective
Review of Medical Records from 616 Patients. JCM .
2019;8(9):1481-1496. doi:10.3390/jcm8091481.
12. Menaker N, Halligan K, Shur N, Paige J, Hickling M. Acute Liver
Failure During Deferasirox Chelation: A Toxicity Worth Considering.J Pediatr Hematol Oncol . 2017;39(3):217-222.
13. Ramaswami A, Rosen DJ, Chu J, Wistinghausen B, Arnon R. Fulminant
Liver Failure in a Child With b-Thalassemia on Deferasirox: A Case
Report. J Pediatr Hematol Oncol . 2017;39(3):235-237.
14. Shah R, Taborda C, Chawla S. Acute and chronic hepatobiliary
manifestations of sickle cell disease: A review. WJGP .
2017;8(3):108-116. doi:10.4291/wjgp.v8.i3.108.
15. Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J. Multisystem
Inflammatory Syndrome in Children during the COVID-19 pandemic: a case
series. The Journal of the Pediatric Infectious Diseases Society .
May 2020:1-25. doi:10.1093/jpids/piaa069/5848127.
16. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe
Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2
epidemic: an observational cohort study. The Lancet .
2020;395(10239):1771-1778. doi:10.1016/S0140-6736(20)31103-X.
17. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of
58 Children With a Pediatric Inflammatory Multisystem Syndrome
Temporally Associated With SARS-CoV-2. JAMA . June 2020:1-11.
doi:10.1001/jama.2020.10369.
18. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in
multisystem inflammatory syndrome in children (MIS-C) in the context of
global SARS-CoV-2 pandemic. Circulation . 2020;382:1370–22.
doi:10.1161/CIRCULATIONAHA.120.048360.
19. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem
inflammatory syndrome in children during the covid-19 pandemic in Paris,
France: prospective observational study. BMJ .
2020;105:m2094-m2097. doi:10.1136/bmj.m2094.
20. Connors JM, Levy JH. COVID-19 and its implications for thrombosis
and anticoagulation. Blood . April 2020:1-21.
doi:10.1182/blood.2020006000.
21. Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal Manifestations
of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong
Kong Cohort and Systematic Review and Meta-analysis.Gastroenterology . March 2020. doi:10.1053/j.gastro.2020.03.065.
22. Ma J, Xia P, Zhou Y, et al. Potential effect of blood purification
therapy in reducing cytokine storm as a late complication of critically
ill COVID-19. Clinical Immunology . 2020;214.
doi:10.1016/j.clim.2020.108408.
23. Keith P, Day M, Perkins L, Lou Moyer, Hewitt K, Wells A. A novel
treatment approach to the novel coronavirus: an argument for the use of
therapeutic plasma exchange for fulminant COVID-19. Critical
Care . 2020;24(1):128-131. doi:10.1186/s13054-020-2836-4.